AtriCure | ATRC

Stock Price
35.38
Daily Change
-0.28 -0.79%
Monthly
-3.12%
Yearly
34.83%
Q3 Forecast
35.09

Peers Price Chg Day Year Date
Abbott 132.94 0.13 0.10% 16.68% Sep/05
AtriCure 35.38 -0.28 -0.79% 34.83% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Becton, Dickinson and Co. 192.39 1.13 0.59% -17.28% Sep/05
Boston Scientific 107.22 -0.07 -0.07% 31.36% Sep/05
Cooper Companies 68.09 0.09 0.13% -36.13% Sep/05
Dexcom 80.51 -0.25 -0.31% 17.11% Sep/05
Edwards Lifesciences 80.94 -0.02 -0.02% 21.19% Sep/05
Globus Medical 60.60 0.31 0.51% -13.42% Sep/05
Integra LifeSciences 15.99 0.34 2.17% -13.57% Sep/05
Intuitive Surgical 466.86 12.34 2.72% -1.06% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Masimo 147.19 4.18 2.92% 31.97% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Merit Medical Systems 92.97 0.82 0.89% -3.74% Sep/05
Insulet 348.43 1.96 0.57% 62.25% Sep/05
ResMed 277.05 3.24 1.18% 13.23% Sep/05
Stryker 392.31 -2.03 -0.51% 9.17% Sep/05
Teleflex 130.70 1.61 1.25% -46.61% Sep/05
Tandem Diabetes Care 12.58 0.19 1.53% -70.33% Sep/05
Zimmer Biomet Holdings 105.73 0.97 0.93% 0.76% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

AtriCure traded at $35.38 this Friday September 5th, decreasing $0.28 or 0.79 percent since the previous trading session. Looking back, over the last four weeks, AtriCure lost 3.12 percent. Over the last 12 months, its price rose by 34.83 percent. Looking ahead, we forecast AtriCure to be priced at 35.09 by the end of this quarter and at 34.22 in one year, according to Trading Economics global macro models projections and analysts expectations.

AtriCure, Inc. is a provider of technologies for the treatment of atrial fibrillation (Afib) and related conditions. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage, and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers globally. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation includes Isolator Synergy Clamp and Multifunctional Pens and Linear Ablation Devices. Its Product for open ablation are cryoICE Cryoablation System. Its product for minimally invasive ablation are EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management includes AtriClip System and LARIAT System.